Evidence map›Paper›PMID 39701579›Full record

ArticleInfluenza and other respiratory viruses2024

Singapore's COVID-19 Genomic Surveillance Programme: Strategies and Insights From a Pandemic Year.

Hao Yi Tan, Nur Huda Khamis, Alvin Goh, Tania K L Mah, Benny Yeo, Jie Yin Ngan, Yichen Ding, Cui Lin, Sae-Rom Chae, Phoebe Lee and 1 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hao Yi TanCommunicable Diseases Group, Ministry of Health, Singapore.ORCID 0009-0005-8904-8936
Nur Huda KhamisCommunicable Diseases Group, Ministry of Health, Singapore.
Alvin GohCommunicable Diseases Group, Ministry of Health, Singapore.
Tania K L MahCommunicable Diseases Group, Ministry of Health, Singapore.
Benny YeoNational Public Health Laboratory, Ministry of Health, Singapore.
Jie Yin NganNational Public Health Laboratory, Ministry of Health, Singapore.
Yichen DingNational Public Health Laboratory, Ministry of Health, Singapore.
Cui LinNational Public Health Laboratory, Ministry of Health, Singapore.
Sae-Rom ChaeCommunicable Diseases Group, Ministry of Health, Singapore.
Phoebe LeeCommunicable Diseases Group, Ministry of Health, Singapore.
Zheng Jie Marc HoCommunicable Diseases Group, Ministry of Health, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the COVID-19 pandemic, genomic surveillance was crucial for monitoring virus spread and identifying variants. Effective surveillance helped understand transmission dynamics. Singapore had success in combating COVID-19 through its surveillance programmes. This paper outlines Singapore's strategy and its impact on public health during the transition to endemicity over 54 weeks from February 2022 to February 2023.

methodsIn May 2022, Singapore expanded its acute respiratory infections (ARI) surveillance to enhance COVID-19 detection. COVID-19-positive samples from ARI cases were sent to the National Public Health Laboratory for whole genome sequencing (WGS). WGS data informed public health actions based on transmission origins and case severity.

resultsOver 54 weeks, NPHL sequenced 18,918 (73%) samples. Analysis showed 29% imported and 71% local cases. Severe cases accounted for 12% and were mostly elderly, specifically those aged 80 years old and above. Variant analysis identified 11 predominant variants and 288 subvariants. Omicron BA.2, BA.5 and XBB were initially dominant, followed by increased variant heterogeneity. Severe cases mirrored these trends.

conclusionGenomic surveillance was integral in Singapore's COVID-19 response, guiding timely public health decisions. Effective variant tracking supported proactive measures. The experience underscores the importance of genomic surveillance for future pandemic preparedness and emerging disease detection, emphasising its role in shaping pandemic responses and global health.

Indexed as

COVID-19SARS-CoV-2Whole Genome SequencingAdolescentAdultAgedAged, 80 and overChildChild, PreschoolEpidemiological MonitoringFemaleGenome, ViralGenomicsHumansInfantInfant, NewbornAcute Respiratory Infections (ARI)COVID‐19Emerging infectious diseasesGenomic SurveillanceHealth StrategyPandemic preparednessSingaporeWhole genome sequencing (WGS)

Identifiers

PMID39701579
PMCPMC11658827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.